Pancreatic Cancer Research

ResearcherJichi Medical UniversityNo recent work listed

Tsutomu Chiba

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109215302. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers

Papers 11

  1. Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-21-1255↗
  2. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  3. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2745↗
  4. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Co-author DOI 10.1136/gutjnl-2017-315425↗
  5. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2018.03.039↗
  6. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Last author DOI 10.1007/s10147-015-0864-x↗
  7. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Last author DOI 10.1002/cam4.204↗
  8. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Last author DOI 10.1097/mpa.0000000000000050↗
  9. Perfusion in the tissue surrounding pancreatic cancer and the patient's prognosis. Last author DOI 10.1155/2014/648021↗
  10. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00280-010-1470-2↗
  11. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takahisa Maruno · 5 shared papers, 2018–2021 · strength 0.43
  2. Hiroshi Seno · 5 shared papers, 2018–2021 · strength 0.43
  3. Motoyuki Tsuda · 5 shared papers, 2018–2021 · strength 0.43
  4. Shinji Üemoto · 6 shared papers, 2014–2021 · strength 0.37
  5. Kyoichi Takaori · 6 shared papers, 2014–2021 · strength 0.37
  6. Yuzo Kodama · 6 shared papers, 2014–2021 · strength 0.36
  7. Kozo Ikuta · 3 shared papers, 2018–2021 · strength 0.25
  8. Satoshi Ogawa · 3 shared papers, 2018–2021 · strength 0.25
  9. Akihisa Fukuda · 3 shared papers, 2018–2021 · strength 0.25
  10. Yoshihiro Nishikawa · 3 shared papers, 2014–2021 · strength 0.24
  11. Tomoaki Matsumori · 2 shared papers, 2020–2021 · strength 0.18
  12. Toshihiro Morita · 2 shared papers, 2020–2021 · strength 0.18
  13. Masashi Kanai · 4 shared papers, 2011–2016 · strength 0.15
  14. Yoshito Kimura · 2 shared papers, 2018–2019 · strength 0.14
  15. Peng Xue · 3 shared papers, 2014–2016 · strength 0.12
  16. Dieter Saur · 1 shared paper, 2021 · strength 0.11
  17. Kenji Masuo · 1 shared paper, 2019 · strength 0.07
  18. Yuto Kimura · 1 shared paper, 2019 · strength 0.07
  19. Shigeo Takaishi · 1 shared paper, 2019 · strength 0.07
  20. Toshihiko Masui · 2 shared papers, 2011–2016 · strength 0.07
  21. Shujiro Yazumi · 2 shared papers, 2011–2016 · strength 0.07
  22. Osamu Araki · 1 shared paper, 2018 · strength 0.06
  23. Tadayuki Kou · 1 shared paper, 2016 · strength 0.04
  24. Manabu Muto · 1 shared paper, 2016 · strength 0.04
  25. Akira Kurita · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.